Dichlororibofuranosylbenzimidazole
"Dichlororibofuranosylbenzimidazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Descriptor ID |
D004004
|
| MeSH Number(s) |
D13.570.800.330
|
| Concept/Terms |
Dichlororibofuranosylbenzimidazole- Dichlororibofuranosylbenzimidazole
- Dichlorobenzimidazole Riboside
- Riboside, Dichlorobenzimidazole
- 5,6-Dichloro-1-beta-D-ribofuranosyl-1-H-benzimidazol
- 5,6 Dichloro 1 beta D ribofuranosyl 1 H benzimidazol
- DRB
- 5,6-Dichloro-1-beta-ribofuranosylbenzimidazole
- 5,6 Dichloro 1 beta ribofuranosylbenzimidazole
|
Below are MeSH descriptors whose meaning is more general than "Dichlororibofuranosylbenzimidazole".
Below are MeSH descriptors whose meaning is more specific than "Dichlororibofuranosylbenzimidazole".
This graph shows the total number of publications written about "Dichlororibofuranosylbenzimidazole" by people in this website by year, and whether "Dichlororibofuranosylbenzimidazole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dichlororibofuranosylbenzimidazole" by people in Profiles.
-
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J Infect Dis. 2024 Feb 14; 229(2):413-421.
-
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clin Infect Dis. 2022 09 10; 75(4):690-701.
-
Inhibition of P-TEFb by DRB suppresses SIRT1/CK2a pathway and enhances radiosensitivity of human cancer cells. Anticancer Res. 2014 Dec; 34(12):6981-9.
-
Casein kinase II inhibition reverses pain hypersensitivity and potentiated spinal N-methyl-D-aspartate receptor activity caused by calcineurin inhibitor. J Pharmacol Exp Ther. 2014 May; 349(2):239-47.
-
Protein kinase CK2 increases glutamatergic input in the hypothalamus and sympathetic vasomotor tone in hypertension. J Neurosci. 2011 Jun 01; 31(22):8271-9.
-
Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemother Pharmacol. 2010 Feb; 65(3):427-36.
-
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2001; 2(10):RESEARCH0041.
-
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin Cancer Res. 2001 Feb; 7(2):267-76.
-
Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol. 1997 Dec; 17(12):7306-16.
-
Transforming growth factor beta 1 inhibition of p34cdc2 phosphorylation and histone H1 kinase activity is associated with G1/S-phase growth arrest. Mol Cell Biol. 1991 Mar; 11(3):1185-94.